Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02494700 | Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 |
| clinicaltrials |
| NCT05799144 | pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer | recruiting | Phase 2 | 54 | Michael K. GibsonOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07214987 | PDT For Induction Therapy For Head And Neck Cancer | recruiting | Phase 2 | 26 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | active not recruiting | Phase 1 / Phase 2 | 41 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04858269 | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | active not recruiting | Phase 2 | 31 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03942653 | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | active not recruiting | Phase 2 | 20 | Manish PatelOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05813626 | Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 89 | Zhejiang Cancer HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07586124 | Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 80 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07601737 | Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 182 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692997 | Sancai Fengsui Decoction for RTOM: A Multicenter RCT | not yet recruiting | Phase 2 | 126 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | active not recruiting | Phase 2 | 87 | Vyriad, Inc.INDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT06788002 | LDRT and Chemoimmunotherapy in NPC With Liver Metastasis(Light) | recruiting | Phase 2 | 26 | Hunan Cancer HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07149207 | Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors | recruiting | Phase 2 | 30 | Medical University of South CarolinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04238624 | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04831320 | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | active not recruiting | Phase 2 | 46 | Washington University School of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07136545 | A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial) | recruiting | Phase 1 / Phase 2 | 50 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck(ZANACC) | not yet recruiting | Phase 2 | 51 | UNICANCEROTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | active not recruiting | Phase 2 / Phase 3 | 384 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT06919666 | NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 29 | University of Colorado, DenverOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07010120 | A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 29 | West China HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07213934 | Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 40 | University of CincinnatiOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | not yet recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT02581137 | Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04151082 | High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors | recruiting | Phase 1 / Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 33 | Jochen LorchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07094685 | Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer(SENIOR-HN) | recruiting | Phase 2 | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04862650 | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 2 | 46 | Marcelo BonomiOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma(PANDA) | not yet recruiting | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT04925544 | Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | active not recruiting | Phase 2 | 13 | Stanford UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06118086 | Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | recruiting | Phase 1 / Phase 2 | 125 | Remix TherapeuticsINDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT03529422 | Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | active not recruiting | Phase 2 | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05726370 | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | recruiting | Phase 2 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05996523 | Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06592599 | Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) | recruiting | Phase 2 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07662681 | Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07662746 | Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 29 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 15, 2026source: clinicaltrials